In this deep-dive episode, we unpack Bysanti (Milsaperidone) FDA Approval: What PMHNPs Need to Know. Bysanti (milsaperidone) is a newly FDA-approved atypical antipsychotic with a unique dual mechanism — partial D2 agonism combined with 5-HT2A inverse agonism — designed to reduce metabolic side effects and EPS risk compared to older atypicals. It’s approved for schizophrenia and bipolar I maintenance in adults. For PMHNPs, this means a new tool with a potentially better tolerability profile, but it requires understanding the monitoring protocol and where it fits in your prescribing algorithm before reaching for it. Read the full post: https://psychnpfellowship.com/bysanti-milsaperidone-fda-approval-pmhnp-guide/